Ann Robinson reviews the latest research The ancient Sumerians and Egyptians used willow bark containing salicylates to treat pain and fevers more than 3500 years ago. In 1897, Bayer chemist Felix Hoffmann synthesised the first aspirin tablet, and 70 years later John Vance explained that it works by inhibiting prostaglandins. Today, aspirin remains one of the most widely used drugs worldwide and new indications for its use can still get researchers excited. This preliminary phase 2 trial of 80 adults with metabolic dysfunction-associated steatotic liver disease (MASLD) found that six months of taking daily, low dose aspirin (81 mg) significantly reduced their total hepatic fat quantity compared with placebo (−6.6% v 3.6%, mean difference −10.2%) and increased the number of participants achieving 30% hepatic fat reduction (42.5% v 12.5%). The rationale is that reducing hepatic fat prevents inflammation, fibrosis, and eventual progression to liver failure. But further study in a larger sample size is necessary to confirm these potentially important findings and …

中文翻译：

---

阿司匹林的新用途……以及其他研究

安·罗宾逊（Ann Robinson）回顾最新研究 3500多年前，古代苏美尔人和埃及人就使用含有水杨酸盐的柳树皮来治疗疼痛和发烧。 1897 年，拜耳化学家菲利克斯·霍夫曼 (Felix Hoffmann) 合成了第一片阿司匹林片剂，70 年后约翰·万斯 (John Vance) 解释说，它通过抑制前列腺素发挥作用。如今，阿司匹林仍然是全世界使用最广泛的药物之一，其使用的新适应症仍然可以让研究人员兴奋不已。这项对 80 名患有代谢功能障碍相关脂肪肝病 (MASLD) 的成年人进行的初步 2 期试验发现，与安慰剂相比，每天服用低剂量阿司匹林 (81 毫克) 六个月可显着降低他们的肝脏脂肪总量 (−6.6% v 3.6) %，平均差-10.2%），并增加了实现肝脂肪减少 30% 的参与者数量（42.5% vs 12.5%）。其基本原理是减少肝脂肪可以防止炎症、纤维化以及最终进展为肝衰竭。但有必要进行更大样本量的进一步研究，以证实这些潜在的重要发现……